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Abstract 
Background: To date, no genetic analysis of inherited retinal disease (IRD) using whole‑exome sequencing (WES) 
has been conducted in a large‑scale Korean cohort. The aim of this study was to characterise the genetic profile of IRD 
patients in Korea using WES.
Methods: We performed comprehensive molecular testing in 168 unrelated Korean IRD patients using WES. The 
potential pathogenicity of candidate variants was assessed using the American College of Medical Genetics and 
Genomics and the Association for Molecular Pathology variant interpretation guidelines, in silico prediction tools, 
published literature, and compatibility with known phenotypes or inheritance patterns.
Results: Causative variants were detected in 86/168 (51.2%) IRD patients, including 58/107 (54.2%) with retinitis 
pigmentosa, 7/15 (46.7%) with cone and cone‑rod dystrophy, 2/3 (66.6%) with Usher syndrome, 1/2 (50.0%) with 
congenital stationary night blindness, 2/2 (100.0%) with Leber congenital amaurosis, 1/1 (100.0%) with Bietti crystal‑
line dystrophy, 1/1 (100.0%) with Joubert syndrome, 9/10 (90.0%) with Stargardt macular dystrophy, 1/10 (10.0%) with 
vitelliform macular dystrophy, 1/11 (9.1%) with other forms of macular dystrophy, and 3/4 (75.0%) with choroiderae‑
mia. USH2A, ABCA4, and EYS were the most common causative genes associated with IRD. For retinitis pigmentosa, 
variants of USH2A and EYS were the most common causative gene mutations.
Conclusions: This study demonstrated the distribution of causative genetic mutations in Korean IRD patients. The 
data will serve as a reference for future genetic screening and development of treatment modalities for Korean IRD 
patients.
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Background
Inherited retinal degeneration (IRD) is a group of clini-
cally and genetically heterogeneous diseases, includ-
ing retinitis pigmentosa (RP) and allied diseases, 
characterised by the progressive loss of photoreceptors 
and/or retinal pigment epithelial cells due to genetic 
anomalies related to the phototransduction cascade, reti-
nal transcription factor-related pathway, RNA splicing 
machinery, retinal metabolism, retinal cell structure, and 
ciliary structure and function [1, 2]. To date, more than 
270 genes have been identified for IRD, as listed in the 
Retinal Information Network [3].
Presently, a diagnosis of IRD is based mainly on clini-
cal findings, including the primarily involved anatomical 
location or cell types, disease progression, and involve-
ment of additional organs [1, 4]. However, the variable 
age of onset, genotypic heterogeneity (one phenotype can 
be caused by multiple genes), phenotypic heterogeneity 
(various mutations in a single gene result in numerous 
phenotypes), incomplete penetrance, unclear inheritance, 
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and progressive nature of IRD, impede a definitive diag-
nosis [1]. Thus, molecular genetic testing is imperative 
for a definitive IRD diagnosis.
We previously reported that the hereditary features 
and mutation profile of Korean patients with IRD differed 
from those of Chinese and Japanese patients, as well as 
patients of other ethnicities [5–7]. However, no genetic 
analysis of IRD using whole-exome sequencing (WES) 
has been conducted in a large-scale Korean cohort. The 
aim of this study was to investigate the mutation spec-




A cohort of 168 unrelated Korean patients with IRD 
was recruited from the Department of Ophthalmology, 
Seoul National University Hospital (SNUH), from Octo-
ber 2008 to January 2019. A detailed family history was 
obtained from each patient to construct a pedigree. All 
patients underwent a detailed ophthalmic history and 
ophthalmic examinations, including best-corrected vis-
ual acuity, slit-lamp biomicroscopy, fundus photography, 
optical coherence tomography, fluorescein angiography, 
visual field tests, and full-field electroretinograms. Clini-
cal diagnosis was determined by at least two retinal spe-
cialists (DJM and UCP).
Comparison of exome capture products
In preparation for higher-throughput exome sequencing 
using the NextSeq500 (Illumina, San Diego, CA, USA), 
we evaluated the evenness, depth, duplication rate, and 
fraction sequenced to ≥ 20 × depth of three exome cap-
ture products: SureSelect Human All Exon v6 (Agilent 
Technologies, Santa Clara, CA, USA) with 150 bp paired-
end reads or with 350  bp paired-end reads, and xGen 
Lockdown panel (Integrated DNA Technologies, Coral-
ville, IA, USA) with 150 bp paired-end reads. The even-
ness score describes the uniformity of the base coverage 
over the target regions, and was calculated according to 
the method described by Mokry et  al. [8]. In addition, 
sensitivity and positive predictive value of variant call-
ing in comparison to a reference genome were calculated. 
To reduce experimental variables and minimise bias 
between libraries, all libraries were prepared using the 
Topomize DNA LT Library Prep Kit (MCLAB, South San 
Francisco, CA, USA). Agilent captures were hybridised as 
single sample reactions using 500 ng of library as input. 
Integrated DNA Technologies captures were hybridised 
as pools of three samples using 500  ng of library input. 
All hybridisation and post-hybridisation captures, and 
washes were performed according to each respective 
manufacturer’s protocol. The same samples were used 
for all exon capture methods (three sets of three identical 
samples).
WES
WES was performed at the Genomics core facility of the 
Center for BioMarkers (SNUH, South Korea) using an 
Illumina NextSeq500. For sequencing on the NextSeq500 
platform, libraries were generated using the Topomize 
DNA LT Library Prep Kit and the hybridisation capture 
of DNA libraries was performed with xGen Lockdown 
panels to generate 150  bp paired-end reads. Sequenced 
reads were aligned to UCSC hg19 human reference 
genome downloaded from the GATK website (https 
://gatk.broad insti tute.org). Alignment of the sequence 
reads, indexing of the reference genome, variant calling, 
and annotation were performed with a pipeline based on 
Burrows-Wheeler Alignment [9] using BaseSpace Onsite 
(Illumina). Variants were annotated using Alamut-HT 
and visualised on Alamut Viewer 2.2 (Interactive Biosoft-
ware, Rouen, France).
Bioinformatic analysis
After read mapping, the output alignment file was sorted 
using the Genome Analysis Tool Kit (GATK) AddOr-
ReplaceReadGroups [10]. Potential polymerase chain 
reaction duplicates were removed using GATK MarkDu-
plicates. GATK BaseRecalibrator and ApplyBQSR were 
further used to recalibrate the base quality scores. After 
these pre-processing steps, germline variants were called 
using GATK HaplotypeCaller, while single nucleotide 
polymorphisms and insertion-deletion polymorphisms 
were annotated using Annotate Variation software [11]. 
After variant annotation, low-quality variants that had a 
read depth < 10, variant allele fraction < 10%, or variant 
read count < 2 were removed.
Variants were prioritised based on their presence 
amongst the 271 genes associated with IRD in RetNet [3]. 
Variants were classified according to the recent recom-
mendations of the American College of Medical Genetics 
and Genomics and the Association for Molecular Pathol-
ogy (ACMG/AMP) using InterVar, as follows: patho-
genic, likely pathogenic, uncertain significance, likely 
benign, or benign variant [12–14].
Variants were considered pathogenic when one of the 
following criteria was met: (1) mutation was previously 
described as disease-causing in the Human Gene Muta-
tion Database or published literature [15]; (2) muta-
tion was classified as pathogenic or likely pathogenic 
according to the ACMG/AMP guidelines; (3) mutation 
was predicted as likely damaging, deleterious, disease-
causing, and medium or high impact by more than 
half of the six pathogenicity prediction tools, includ-
ing SIFT [16], PolyPhen‐2 HDIV and PolyPhen‐2 Hvar 
Page 3 of 12Ma et al. BMC Med Genomics           (2021) 14:74  
[17], MutationTaster [18], MutationAssesor [19], and 
FATHMM [20]; or (4) a resultant protein truncation 
mutation, such as a nonsense or frameshift (insertion 
or deletion) mutation, was identified. All variants not 
compatible with known phenotypes or inheritance pat-
terns were excluded.
Patients were determined to have causative variant(s) 
when (1) one pathogenic variant was present in a gene 
with autosomal dominant (AD) or X-linked (XL) inher-
itance; (2) two heterozygous variants or one homozy-
gous pathogenic variant was present in a gene with 
autosomal recessive (AR) inheritance. Patients were 
determined to have possible causative variant(s) when 
one heterozygous pathogenic variant was present in a 
gene with AR inheritance. Patients were determined to 
have no causative variants when no (possible) patho-
genic variant was detected.
Variant validation
Additional Sanger sequencing was performed for all 
pathogenic variants with a coverage < 20 reads. Only 
5/177 variants (2.8%) have coverage < 20 reads, all of 
which were successfully sequenced. The concordance 
rate was 100.0% (5/5).
Statistical analysis
To compare the performance of the exon capture prod-
ucts, we applied the Mann–Whitney U-test. All statis-
tical analyses were performed using SPSS software for 
Windows, version 22.0 (IBM, Armonk, NY, USA). A 
value of P < 0.05 was regarded as statistically significant.
Results
Patients
We analysed samples from 168 unrelated Korean patients 
with IRD (77 females, 91 males). The mean patient age 
was 42.8 ± 15.9  years (range: 10.4–85.4; median: 37.1). 
Among these patients, 133 (79.2%) had photoreceptor 
disease, 33 (19.6%) had macular disease, and 2 (1.2%) 
had choroideraemia (Table 1). RP was the most common 
form of IRD (60.7%).
Based on their family pedigrees, 67 (39.9%) of the 
patients were presumed to have IRD with AR inherit-
ance, 35 (20.8%) with AD inheritance, and 6 (3.6%) with 
XL inheritance. Sixty (35.7%) patients were the only 
affected individuals in their family (simplex cases).
Comparison of exome capture products
The evenness score and sensitivity were significantly 
higher for the SureSelect Human All Exon v6 with 350 bp 
paired-end reads than for the other capture products 
(Table 2). The SureSelect Human All Exon v6 with 150 bp 
paired-end reads and xGen Lockdown panel produced 
statistically equivalent results. The depth and duplication 
rate were highest for the SureSelect Human All Exon v6 
with 150  bp paired-end reads, then for the xGen Lock-
down panel, and lowest for the SureSelect Human All 
Exon v6 with 350 bp paired-end reads. The positive pre-
dictive value was highest for the xGen Lockdown panel, 
then for the SureSelect Human All Exon v6 with 150 bp 
Table 1 Clinical details of 168 Korean patients with inherited retinal degeneration
Clinical details n (%)
Clinical diagnosis Photoreceptor disease Retinitis pigmentosa 102 (60.4%)
Cone and cone‑rod dystrophy 22 (13.1%)
Usher syndrome 3 (1.8%)
Congenital stationary night blindness 2 (1.2%)
Leber congenital amaurosis 2 (1.2%)
Bardet–Biedl syndrome 1 (0.6%)
Joubert syndrome 1 (0.6%)
Macular disease Stargardt macular dystrophy 13 (7.7%)
Vitelliform macular dystrophy 11 (6.5%)
North Carolina macular dystrophy 1 (0.6%)
Other macular dystrophy 8 (4.8%)
Choroideraemia 2 (1.2%)
Inheritance pattern Autosomal recessive 67 (39.9%)
Autosomal dominant 35 (20.8%)
X‑linked 6 (3.6%)
Simplex 60 (35.7%)
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paired-end reads, and lowest for the SureSelect Human 
All Exon v6 with 350 bp paired-end reads.
The fraction of nucleotides covered to a 
depth ≥ 20 × did not differ among the exome capture 
products. In summary, the xGen Lockdown panel dem-
onstrated noninferiority to the SureSelect Human All 
Exon v6, and further exome capture for WES was per-
formed using the xGen Lockdown panel.
Identification of pathogenic variants
We identified disease-causing variants in 86 (51.2%) 
patients (Additional file  1: Table  S1). In all, 147 mutant 
alleles were identified in 35 known IRD-related genes. 
Among these mutant alleles, 96 (65.3%) had a previously 
reported association with IRD, and 51 (34.7%) were novel 
variants in defined IRD genes. Amongst the identified 
disease-associated variants, 89 (60.5%) were missense 
variants, 26 (17.7%) were nonsense variants, 25 (17.0%) 
were frameshift deletions or insertions, and 7 (4.8%) were 
predicted to affect splicing. USH2A was the most com-
mon causative gene amongst the known disease-associ-
ated genes (15.1% of cases), followed by ABCA4 (14.0%) 
(Fig. 1).
Table S1 (see Additional file 1) [21–62]
Molecular diagnosis redefined inheritance pattern 
and clinical diagnosis
All patients who received a definite molecular diagno-
sis had their clinical diagnosis and inheritance pattern 
redefined based on the genetic findings (Additional file 1: 
Table S1). Figure 2 shows a comparison of the mutation 
detection rates for various IRDs after reclassification. The 
following are two representative cases.
Case 55, who had been clinically diagnosed with RP, 
had macular-sparing photoreceptor degeneration with 
diffuse bone spicule pigmentation and degeneration 
of the retinal pigment epithelium and choriocapillaris 
(Fig.  3). WES identified causative variants in the CHM 
gene, and the clinical diagnosis for case 55 was redefined 
as choroideraemia. Case 147 was clinically diagnosed 
with RP with generalised photoreceptor, retinal pigment 
epithelium, and choriocapillaris degeneration with dif-
fuse bone spicule pigmentation (Fig.  4). WES identified 
causative variants in the CYP4V2 gene, and the clinical 
diagnosis for case 147 was redefined as Bietti crystal-
line dystrophy. Fundus photographs from 9  years prior 
to sequencing showed many shiny yellow deposits in the 
posterior pole, which are consistent with Bietti crystal-
line dystrophy.
Fifty-five patients (32.7%) had their inheritance pat-
terns redefined based on the genetic findings. Of the 37 
simplex cases, 35 patients (94.6%) were reclassified as 
having AR inheritance, while AD inheritance and XL 
inheritance were diagnosed in one patient each (2.7%).
Non‑syndromic RP
After refinement of clinical diagnosis, 107 patients 
received molecular diagnosis of RP, comprising 63.7% of 
the total cohort. We identified causative variants for 58 
of the 107 (54.2%) patients, including 96 variants in 26 
genes (Additional file  1: Table  S1). Variants in USH2A 
were the most common, which were carried by 13 
patients (22.4%), followed by EYS variants in six patients 
(10.3%; Fig. 5).
RHO (3, 25.0%) was the most commonly identified 
mutated gene in 12 RP patients with AD inheritance 
(adRP; 20.7%), USHA2A (13, 31.0%) and EYS (6, 14.3%) 
Table 2 Comparison of exome capture products
SD standard deviation
a Three sets of three identical samples
b P value comparing SureSelect Human All Exon v6 150-bp paired-end reads with 350-bp paired-end reads
c P value comparing SureSelect Human All Exon v6 150-bp paired-end reads with xGen Lockdown panel
d P value comparing SureSelect Human All Exon v6 350-bp paired-end reads with xGen Lockdown panel
SureSelect Human All Exon v6 xGen Lockdown 
panel (n =  9a)
P valueb P  valuec P  valued
150‑bp paired‑end 
reads (n =  9a)
350‑bp paired‑end 
reads (n =  9a)
Mean ± SD Mean ± SD Mean ± SD
Evenness (%) 75.3 ± 5.7 79.9 ± 0.4 76.6 ± 0.1 < 0.001 0.258 < 0.001
Depth (x) 61.3 ± 3.8 47.6 ± 0.5 56.3 ± 1.1 < 0.001 < 0.001 < 0.001
Duplication rate (%) 33.4 ± 2.4 17.5 ± 0.2 22.9 ± 0.4 < 0.001 < 0.001 < 0.001
 ≥ 20 × depth fraction (%) 87.9 ± 7.4 90.8 ± 0.6 91.3 ± 0.2 0.258 0.258 0.258
Sensitivity (%) 94.9 ± 4.0 97.8 ± 0.1 96.5 ± 0.2 < 0.001 0.258 < 0.001
Positive predictive value (%) 74.9 ± 0.7 73.8 ± 0.2 76.1 ± 0.2 < 0.001 < 0.001 < 0.001
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were the most commonly identified mutated genes in 42 
RP patients with AR inheritance (arRP; 72.4%), and RPGR 
(2, 50%) was the most commonly identified mutated gene 
in four RP patients with XL inheritance (xlRP, 6.9%).
Cone and cone‑rod dystrophy
Amongst the 15 cone and cone-rod dystrophy (CORD) 
patient cases, we identified causative variants in seven 
patients (46.7%) (Additional file  1: Table  S1). CRX (2, 
28.6%) was the most commonly identified mutated gene.
Stargardt macular dystrophy
Of the 13 patients with an initial clinical diagnosis of 
Stargardt macular dystrophy (STGD), three patients were 
reclassified as having CORD or other macular dystro-
phy based on the genetic findings. WES revealed causa-
tive variants for 9 out of the 10 remaining STGD patients 
and a possible causative variant for the tenth patient. All 
identified causative variants were of the  ABCA4 gene 
(Additional file 1: Table S1).
Possible pathogenic variants were identified
A further 17.9% (30/168) of the patients received a possi-
ble molecular diagnosis based on identification of a single 
pathogenic variant in a gene known to be associated with 
AR IRD that was compatible with known phenotypes or 
Fig. 1 USH2A and ABCA4 mutations were the most common causative variants among inherited retinal degeneration patients. All data are from the 
present study
Fig. 2 The number of detected pathogenic mutations for each 
disease phenotype. BBS Bardet–Biedl syndrome, Bietti Bietti crystalline 
dystrophy, CHM choroideraemia, CSNB congenital stationary night 
blindness, CORD cone and cone‑rod dystrophy, Joubert Joubert 
syndrome, LCA Leber congenital amaurosis, MD other macular 
dystrophy, NCMD North Carolina macular dystrophy, RP retinitis 
pigmentosa, STGD Stargardt macular dystrophy, Usher Usher 
syndrome, VMD vitelliform macular dystrophy
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inheritance patterns (Additional file 2: Table S2). Overall, 
69.0% (116/168) of study participants received a definite 
or possible molecular diagnosis after WES testing.
Table S2 (see Additional file 2) [21–70]
Discussion
In this study, we employed a single genetic test, WES, for 
the genetic diagnosis of 168 unrelated Korean patients 
with different types of IRD. Using this single test, we 
molecularly diagnosed 86 (51.2%) patients. To the best 
of our knowledge, this is the first study to evaluate clini-
cal diagnostic accuracy and causative genes in Korean 
patients with various IRD using a WES approach.
Targeted sequence capture is used to isolate and 
enrich specific genomic regions prior to massively par-
allel sequencing. Although the cost of WES is gradually 
decreasing, it remains expensive for clinical use. Herein, 
we used pre-capture pooling with targeted sequence cap-
ture to reduce the reagent cost and hands-on time. As 
pre-capture pooling using xGen Lockdown panel was not 
inferior to routine post-capture pooling using SureSelect 
Human All Exon v6, we successfully utilised the xGen 
panel for WES in Korean IRD patients. We identified 
147 causative variants in 35 known IRD-related genes, 
including 51 (34.7%) novel variants. However, most of 
these novel variants were potentially causative which 
were annotated by computational tools. Functional vali-
dation would be required to derive a definite causality of 
these potentially causative variant.
Several studies have reported that the hereditary fea-
tures and causative genes of IRD vary among ethnici-
ties, even in geopolitically close Asian countries [5–7, 29, 
71–73]. However, only a few reports have been published 
on the mutation spectrum of a large-scale Korean cohort 
with IRD. Our previous study using targeted exome 
sequencing (TES) of 53 RP-related genes in 62 Korean 
patients with non-syndromic RP revealed causal variants 
in 50.0% of the patients [7]. PRPF31 mutations (17.6%) 
were the most frequently found causative variants, fol-
lowed by mutations in EYS, PDE6B, RHO, RP1, and RP2 
(11.8% each). A recent study reported the TES results for 
204 IRD-related genes in 86 Korean patients with IRD 
Fig. 3 Clinical phenotypes of case 55, who carries a hemizygous mutation in the CHM gene. a, b Colour fundus photograph. c, d Optical coherence 
tomography images. e, f Vision field diagram. g Electroretinography recording
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[74], as well as the molecular diagnoses rate for 44.2% 
of the patients. In RP, EYS mutations (22.2%) were the 
most frequent causative variants, followed by mutations 
in PED6B (16.7%), PED6A (11.1%), and USH2A (11.1%). 
In the present study, USH2A mutations (22.4%) were 
the most common causative variants in RP, followed by 
variants in EYS (10.3%), RP1 (6.9%), and ABCA4, PED6B, 
and RHO (5.2% each) mutations. The differences in the 
mutation spectra amongst the Korean studies appears to 
largely originate from selection of the sample population.
Moreover, the sample sizes of the two previous studies 
were much smaller than that of the present study making 
them more vulnerable to sampling error. In addition, the 
inclusion of many subjects from a single family can result 
in increased representation of a specific genetic muta-
tion, thereby skewing the mutational spectrum. In the 
present study, we only included one proband from each 
family to maximise the representativeness of the cohort 
for the total population and to reduce sampling error. In 
addition, differing inheritance pattern distributions in the 
sampled populations may result in different distributions 
of causative mutations. Our previous study included a 
large proportion of subjects with AD inheritance, which 
resulted in a higher proportion of mutations in PRPF31, 
an AD inheritance gene [7]. In the present study, the 
distribution of the inheritance pattern for RP resembles 
that in a previous report on a large cohort of Korean RP 
patients [6].
The mutation spectrum of the patients in the present 
study resembles those established in recent large-scale 
studies in other Asian countries [21, 75]. For instance, 
the USH2A mutation was the most common in the pre-
sent study, as in the Chinese study, and it was the second 
most common in the Japanese study. The second most 
common mutation was in the EYS gene, which was the 
most common in the Japanese study and the third most 
common in the Chinese study. These findings were simi-
lar to those of previous studies demonstrating ethnic dif-
ferences between Asian and Caucasian populations, with 
a higher incidence of EYS mutations in arRP patients 
of an Asian background than Caucasian background 
[76]. The most common EYS mutation in our cohort 
Fig. 4 Clinical phenotypes of case 147, who carries compound heterozygous mutations in the CYP4V2 gene. a, b Colour fundus photographs taken 
at the time of genetic analysis. c, d Colour fundus photographs from 9 years prior to the study
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was c.4957dupA; it was also common in Japanese RP 
patients, however, was rare, or not detected in European 
RP patients and Chinese RP patients [66, 77]. Meanwhile, 
the c.C8805A and c.C7394G EYS mutations, which were 
frequently observed in the Japanese RP cohort, were not 
detected in Korean studies [7, 74, 78]. This suggests that 
differences in the mutational spectra of IRD patients exist 
among East Asian countries, despite their geographical 
proximity, and emphasises the importance of obtaining 
reference data for individual nations or regions to deter-
mine the local genomic IRD landscape.
The prevalence of the RP1 mutation was 6.9% in arRP 
cases in this study, which was higher than those among 
Japanese and Chinese arRP patients (1.7–2%) [29, 73]. 
Mutations in the RP1 gene cause both AR and AD forms 
of RP, accounting for 5.5% of adRP and less than 1% of 
arRP [76]. Different explanations for the dominant/
recessive mutation effect of the RP1 gene have been pro-
posed, however, the precise mechanism remains unclear. 
In addition, a recent study suggested that the pheno-
typic spectrum associated with RP1 mutations should be 
expanded to CORD and macular dystrophy [79, 80]. In 
our cohort, Case 103, who showed well-demarcated mac-
ular atrophy with normal electroretinography findings 
(see Additional file  3) carried compound heterozygous 
nonsense (c.C5797T) and frameshift (c.649delG) muta-
tions, and received a molecular diagnosis of RP1-associ-
ated AR macular dystrophy.
WES has clear advantages over TES for the molecu-
lar diagnosis of IRD. The heterogeneity of the genotype 
and phenotype, as well as the unclear inheritance pat-
terns of IRD, make it difficult to select target genes for 
TES. In addition, more than 270 causative genes have 
been identified for IRD to date, and new causative genes 
continue to be discovered. To keep pace with the litera-
ture, researchers must redesign panels to incorporate 
new genomic regions at additional expense. In contrast, 
WES provides the advantage of re-evaluating previously 
analysed datasets when a novel gene associated with IRD 
is reported. In a study comparing WES and three com-
mercial gene panels, WES discovered causative gene 
mutations in 42% of cases, which were not included in at 
least one commercial panel [81]. In the present study, six 
genes (CYP4V2, NMNAT1, RP1L1, CACNA1F, BBS2, and 
Fig. 5 Percentages of causative genes identified in 58 retinitis pigmentosa patients. Mutations in EYS and USH2A were the most common in the 
population (a). The proportion of causative genes based on inheritance pattern is shown in b. All data are from the present study
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REEP6) out of 35 causative genes detected in our cohort 
were not included in at least one of the TES studies in 
Korean IRD patients [7, 74].
Among patients with macular disease, patients with 
STGD had the highest detection rate for causative vari-
ants (90.0%), however, patients with other forms had 
a poorer detection rate (9.5%). This is likely due to the 
presence of pathognomonic findings for the accurate 
clinical diagnosis of STGD. Initially, 13 patients with 
clinical diagnosis of STGD were included in this study. 
Three patients who were redefined as having another 
disease based on their molecular diagnosis did not have 
dark choroid rings on fluorescein angiography. In con-
trast, the remaining ten patients had dark choroid signs 
and a (probable) molecular diagnosis of STGD. This 
pathognomonic finding, the dark choroid sign, can dif-
ferentiate STGD from other similar conditions including 
non-hereditary diseases [82]. Meanwhile, all vitelliform 
macular dystrophy cases in our cohort were clinically 
diagnosed as adult-onset vitelliform macular dystrophy 
with clinical findings of submacular vitelliform mate-
rial and normal electrooculogram. The mean age of the 
vitelliform macular dystrophy patients was 64.5  years. 
These clinical features are similar to those of exudative 
age-related macular degeneration, choroidal neovascu-
larisation, or central serous chorioretinopathy, which do 
not belong to the category of IRD. There is a possibility 
that some of our vitelliform macular dystrophy cases may 
arise from non-genetic conditions. This finding suggests 
that accurate clinical diagnosis can increase the efficiency 
of molecular diagnosis.
The 17.9% (30/168) of patients who received a possible 
molecular diagnosis may carry a second pathogenic vari-
ant in the same gene, which occurs in no- or low-coverage 
genetic regions [73]. In the exome sequencing approach, 
some genetic regions have low or no coverage. For exam-
ple, repetitive regions, GC-rich regions, and regions with 
high homology are difficult to enrich. In addition, small 
copy number variations and deep-intronic regions can-
not be detected via exome sequencing [83, 84]. In these 
patients, further analysis, such as direct sequence analy-
sis or whole genome sequencing, is required.
In this study, we were unable to identify any causative 
variants in 31.0% (52/168) of the cases. Several explana-
tions may account for these. The first explanation is the 
limitation of WES. Approximately 85% of known causa-
tive mutations occur in exonic regions that encode 
proteins, indicating that WES is unable to discover the 
cause of the remaining ~ 15% of causative mutations. 
In addition, some genetic regions have low or no cov-
erage in the exome sequencing approach, as described 
above. The second explanation is potentially inaccurate 
clinical diagnosis. It is possible that some of our cohort 
have non-hereditary retinal conditions that phenotypi-
cally resemble IRD. Therefore, further study via direct 
sequence analysis or whole-genome sequencing with 
detailed clinical diagnosis is required to achieve an 
optimal detection rate.
Conclusion
The present study screened the largest sample of 
Korean IRD patients to date and described the genetic 
characteristics of the cohort. Our data will serve as a 
basis for genetic counselling of Korean IRD patients 
and lay the groundwork for the upcoming era of gene 
therapy.
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